Moyamoya Disease Market Overview 2030
Moyamoya disease (MMD) is defined as a chronic cerebrovascular disease characterized by progressive stenosis of the internal carotid artery and abnormal vascular network at the base of the brain. Stroke is one of the important symptoms of moyamoya disease. It can also cause paralysis of the arms, face and legs, language impairment and temporary loss of nerve function of parts of the body. This can occur in any age but more chances in 5-10 years child and 30-50 years in adults. Antiplatelet agents, anticoagulants, and hematologic agents are used for treatment of moyamoya disease.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the moyamoya disease market.
Top Impacting Factors
- Rise in cases of genetic disorders, increase in awareness regarding diagnosis of moyamoya disease, surge in use of surgical moyamoya treatment procedure, rise in mortality rate of moyamoya disease, and increase in geriatric population are the major factors that drive the growth of moyamoya disease market.
- In addition, improvement in reimbursement policies in health care sector, surge in technological advancement & modernisation in health care devices, increase in demand from emerging economies for treatment of brain related diseases, R & D activities to improve quality of drugs & rise in surgical procedures in moyamoya disease, and rise in usage of targeted drug therapies are some factors that fuel the growth of moyamoya disease market.
- However, adverse effects of treatment and presence of misbranded & spurious drugs restrain the growth of moyamoya disease market.
- Contrarily, growth opportunities in emerging market is expected are expected to offer lucrative opportunities for the expansion of the market.
Market Trends
New Product Launches to Flourish the Market
In 2020, Johnson & Johnson announced launch of Cerenovus Stroke Device. This product help to aid physicians in clot removal and surgery of cerebrovascular disease such as moyamoya disease.
In 2019, Valenta Pharma announced launch of new generation antioxidant for treatment of cerebrovascular failure named as Ethoxidol. This product can be used in treatment cerebrovascular disease such as moyamoya disease in brain.
In 2019, Boston Scientific Corporation announced U.S. FDA approval for launch of EXALT model D single use deudenoscope. This product can be used in surgery of brain related to moyamoya diseases and other neurological disease.
Key Benefits of the Report
- This study presents the analytical depiction of moyamoya disease market industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the moyamoya disease market share.
- The current market is quantitatively analyzed to highlight the moyamoya disease market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.
Questions Answered in the Moyamoya Disease Market Report
- Which are the leading players active in the moyamoya disease market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "moyamoya disease"?
- What is "moyamoya disease" market prediction in the future?
- Who are the leading global players in the "moyamoya disease" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "moyamoya disease" market report?
Moyamoya Disease Market, by Diagnosis Report Highlights
| Aspects | Details |
 By Diagnosis |
|
 By Treatment |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Abbott, AstraZeneca, Zimmer Biomet, Regeneron Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Eli Lilly and Company, Pfizer Inc., Boehringer Ingelheim International GmbH, Abiogen Pharma S.p.A., Johnson and Johnson Services Inc., GlaxoSmithKline plc., AbbVie Inc., Novartis AG, Ampio Pharmaceuticals Inc. |
Loading Table Of Content...
